Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial

Jonathan McConathy, Vadim S. Koshkin, Yusuf Menda, Jordi Rodon, Ajit H. Goenka, Ryan H. Moy, Sophie Morse, Arnaud Demange, Lars Blumenstein, Burcu Babaoglan, Paola Aimone, Thomas A. Hope

Open source

DOI
10.1158/1078-0432.ccr-25-4356
Published
2026-06-01
Container
Clinical Cancer Research
Publisher
American Association for Cancer Research (AACR)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-25-4356,
  title = {Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial},
  author = {Jonathan McConathy and Vadim S. Koshkin and Yusuf Menda and Jordi Rodon and Ajit H. Goenka and Ryan H. Moy and Sophie Morse and Arnaud Demange and Lars Blumenstein and Burcu Babaoglan and Paola Aimone and Thomas A. Hope},
  year = {2026},
  journal = {Clinical Cancer Research},
  doi = {10.1158/1078-0432.ccr-25-4356},
  url = {https://doi.org/10.1158/1078-0432.ccr-25-4356}
}

RIS

TY  - JOUR
TI  - Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial
AU  - Jonathan McConathy
AU  - Vadim S. Koshkin
AU  - Yusuf Menda
AU  - Jordi Rodon
AU  - Ajit H. Goenka
AU  - Ryan H. Moy
AU  - Sophie Morse
AU  - Arnaud Demange
AU  - Lars Blumenstein
AU  - Burcu Babaoglan
AU  - Paola Aimone
AU  - Thomas A. Hope
PY  - 2026
JO  - Clinical Cancer Research
DO  - 10.1158/1078-0432.ccr-25-4356
UR  - https://doi.org/10.1158/1078-0432.ccr-25-4356
ER  - 

APA

McConathy, J., Koshkin, V. S., Menda, Y., Rodon, J., Goenka, A. H., Moy, R. H., Morse, S., Demange, A., Blumenstein, L., Babaoglan, B., Aimone, P., & Hope, T. A. (2026). Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-25-4356

Source records